ProShare Advisors LLC raised its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 42.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 932,624 shares of the company’s stock after acquiring an additional 277,765 shares during the period. ProShare Advisors LLC owned approximately 0.06% of Astrazeneca worth $163,676,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in AZN. Triumph Capital Management acquired a new stake in shares of Astrazeneca during the third quarter valued at about $25,000. Bangor Savings Bank boosted its stake in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca in the fourth quarter valued at approximately $30,000. Rakuten Investment Management Inc. purchased a new position in shares of Astrazeneca in the third quarter valued at approximately $31,000. Finally, YANKCOM Partnership purchased a new position in shares of Astrazeneca in the fourth quarter valued at approximately $31,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
More Astrazeneca News
Here are the key news stories impacting Astrazeneca this week:
- Positive Sentiment: Baxfendy (baxdrostat) won U.S. approval as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension, giving AstraZeneca a first-in-class drug in a large market and raising expectations for meaningful future sales. Article: AstraZeneca’s blood pressure drug wins U.S. approval
- Positive Sentiment: Enhertu received FDA approval for two new HER2-positive early breast cancer settings, expanding the antibody-drug conjugate’s use and potentially boosting AstraZeneca’s oncology revenue through a broader patient population. Article: AZN, Daiichi’s Enhertu Gets FDA Nod for Two New Breast Cancer Settings
- Neutral Sentiment: Additional coverage highlighted AstraZeneca’s broader pipeline momentum, reinforcing investor interest in the company’s growth story, but without adding new material information beyond the FDA wins. Article: AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu
Astrazeneca Stock Up 1.3%
Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, research analysts forecast that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on AZN shares. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Thursday, May 14th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Thursday, April 30th. Finally, Citigroup started coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $205.33.
Get Our Latest Stock Report on Astrazeneca
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
